TY - JOUR
T1 - Successful PBSC mobilization with high-dose G-CSF for patients failing a first round of mobilization
AU - Gazitt, Y.
AU - Freytes, C. O.
AU - Callander, N.
AU - Tsai, T. W.
AU - Alsina, M.
AU - Anderson, J.
AU - Holle, L.
AU - Cruz, J.
AU - Devore, P.
AU - McGrath, M.
AU - West, G.
AU - Alvarez, R.
AU - Montgomery, W.
PY - 1999/5/27
Y1 - 1999/5/27
N2 - PBSC are the preferred source of stem cells for autologous transplantation. However, regardless of the mobilization procedure used, 10%- 20% of patients fail to collect an adequate number to ensure prompt engraftment. There is as yet no standard mobilization procedure for patients who fail a first mobilization attempt. Here, we describe a highly efficient strategy to obtain an adequate number of stem cells for patients who failed a first mobilization attempt. Seventy-four patients with various hematologic malignancies underwent initial mobilization with various regimens including hematopoietic growth factors with or without chemotherapy. In 72% of patients, ≥2 x 106 CD34+ stem cells/kg were collected in the initial mobilization attempt, and patients engrafted in a median of 10 days for neutrophils and 12 days for platelets. Eighteen patients failed to mobilize adequate numbers of stem cells, defined as the inability to collect 0.2 x 106 CD34+ stem cells/kg/day in the first 2-3 days. These patients had their apheresis halted. Patients were immediately given G-CSF (32 μg/kg/day) for 4 days as a second attempt at mobilization. Eighty-eight percent of these patients achieved the target of ≥2 x 106 CD34+ cells/kg, with a median duration of apheresis of 5 days (including the first and second mobilizations). The mean CD34+ cells/kg/day increased after administration of high-dose G-CSF from 0.16 after the first mobilization attempt to 0.61 (p = 0.0002) after the second mobilization. All patients engrafted in a median of 11 and 13 days for neutrophils and platelets, respectively. We conclude that patients whose apheresis yield is <0.4 x 106 CD34+ cells/kg after the first two apheresis collections can be successfully mobilized if high-dose G- CSF is administered immediately and continued until achieving ≥2 x 106 CD34+ stem cells/kg.
AB - PBSC are the preferred source of stem cells for autologous transplantation. However, regardless of the mobilization procedure used, 10%- 20% of patients fail to collect an adequate number to ensure prompt engraftment. There is as yet no standard mobilization procedure for patients who fail a first mobilization attempt. Here, we describe a highly efficient strategy to obtain an adequate number of stem cells for patients who failed a first mobilization attempt. Seventy-four patients with various hematologic malignancies underwent initial mobilization with various regimens including hematopoietic growth factors with or without chemotherapy. In 72% of patients, ≥2 x 106 CD34+ stem cells/kg were collected in the initial mobilization attempt, and patients engrafted in a median of 10 days for neutrophils and 12 days for platelets. Eighteen patients failed to mobilize adequate numbers of stem cells, defined as the inability to collect 0.2 x 106 CD34+ stem cells/kg/day in the first 2-3 days. These patients had their apheresis halted. Patients were immediately given G-CSF (32 μg/kg/day) for 4 days as a second attempt at mobilization. Eighty-eight percent of these patients achieved the target of ≥2 x 106 CD34+ cells/kg, with a median duration of apheresis of 5 days (including the first and second mobilizations). The mean CD34+ cells/kg/day increased after administration of high-dose G-CSF from 0.16 after the first mobilization attempt to 0.61 (p = 0.0002) after the second mobilization. All patients engrafted in a median of 11 and 13 days for neutrophils and platelets, respectively. We conclude that patients whose apheresis yield is <0.4 x 106 CD34+ cells/kg after the first two apheresis collections can be successfully mobilized if high-dose G- CSF is administered immediately and continued until achieving ≥2 x 106 CD34+ stem cells/kg.
UR - http://www.scopus.com/inward/record.url?scp=0032902383&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032902383&partnerID=8YFLogxK
U2 - 10.1089/106161299320442
DO - 10.1089/106161299320442
M3 - Article
C2 - 10349911
AN - SCOPUS:0032902383
VL - 8
SP - 173
EP - 183
JO - Stem Cells and Development
JF - Stem Cells and Development
SN - 1547-3287
IS - 2
ER -